Ischemic stroke
Drug research and approvals for ischemic stroke: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 701 studies of ischemic stroke are recruiting on ClinicalTrials.gov, Health Canada has authorized 12 drug trials for it since 2013, FDA has 0 approved and 4 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 701
- Trials authorized in Canada: 12
- FDA orphan approvals: 0
- EU medicines: 1
- Improving Endovascular Treatment Through Process RefinementsNCT07948694 · Not applicable · Beijing Tiantan Hospital · starts Apr 15, 2026
- Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling DeficitsNCT07944261 · Phase 3 · Shandong Provincial Hospital · starts Oct 15, 2026
- MRS Imaging Evaluation for Acute Minor StrokeNCT07945158 · Not reported · Shanghai Jiao Tong University Affiliated Sixth People's Hospital · starts Aug 3, 2024
- A Feasibility Study of a Wearable Arrhythmia Monitoring System (PulseON) in Stroke PatientsNCT07943065 · Not reported · University Hospitals Coventry and Warwickshire NHS Trust · starts Sep 16, 2026
- Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial Stenosis: A…NCT07935408 · Not reported · Second Affiliated Hospital of Soochow University · starts Mar 1, 2026
- Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation StrokeNCT07933692 · Phase 4 · Shandong Provincial Hospital · starts Oct 1, 2021
- Evaluation of the Predictive Value of Microemboli Detected by Robotic Transcranial Doppler (TCD) for the Occurrence of…NCT07932080 · Not applicable · CHC Montlegia · starts Dec 1, 2026
- Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial StenosisNCT07932639 · Phase 4 · Second Affiliated Hospital of Soochow University · starts Mar 21, 2026
- Integrated PET/MR Assessment of Brain Recovery After Recanalization of Non-Acute Atherosclerotic MCA OcclusionNCT07927569 · Not reported · Qianfoshan Hospital · starts Mar 21, 2024
Approved 1
- ClopidogrelPurinergic receptor P2Y12 antagonist
Phase 3 12 of 33
- AlteplaseTissue-type plasminogen activator exogenous protein
- TenecteplaseTissue-type plasminogen activator exogenous protein
- AspirinCyclooxygenase inhibitor
- Edaravone
- OxygenEssential for cellular homeostasis
- CilostazolPhosphodiesterase 3A inhibitor
- EptifibatideIntegrin alpha-IIb/beta-3 inhibitor
- TicagrelorPurinergic receptor P2Y12 negative allosteric modulator
- ArgatrobanThrombin inhibitor
- PravastatinHMG-CoA reductase inhibitor
- PhenylephrineAdrenergic receptor alpha-1 agonist
- Albumin humanBilirubin sequestering agent
Phase 2 12 of 43
- Ginkgo
- TirofibanIntegrin alpha-IIb/beta-3 inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- Dimethyl fumarateKelch-like ECH-associated protein 1 inhibitor
- Otaplimastat
- ExenatideGlucagon-like peptide 1 receptor agonist
- NatalizumabIntegrin alpha-4/beta-7 inhibitor
- Cinepazide
- Meldonium
- THR-18
- Valproic acidSuccinate semialdehyde dehydrogenase inhibitor
- FluoxetineSerotonin transporter inhibitor
Phase 1 or earlier 12 of 17
- VerapamilVoltage-gated L-type calcium channel blocker
- PerflutrenDiagnostic agent
- WarfarinVitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- ApixabanCoagulation factor X inhibitor
- Insulin humanInsulin receptor agonist
- Human immunoglobulin gReplacement therapy, immunomodulatory effects
- SildenafilPhosphodiesterase 5A inhibitor
- Insulin porkInsulin receptor agonist
- GlyburideSulfonylurea receptor 1, Kir6.2 blocker
- Fibrinolysin, humanFibrinogen inhibitor
- DabigatranThrombin inhibitor
- BMS-986141Proteinase activated receptor 4 antagonist
How its trials ended
2,189 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 388 whose ending is known, 37% met their primary endpoint, 12% missed it and 51% stopped early.
- Ongoing72733%
- Completed, result not reported67831%
- Status unknown39618%
- Met its primary endpoint1426%
- Stopped: other or unclear1095%
- Missed its primary endpoint472%
- Stopped: enrollment or feasibility432%
- Stopped: lack of efficacy191%
- Stopped: sponsor or business decision141%
- Stopped: funding9<1%
- Stopped: safety5<1%
| Sep 25, 2026 | A phase 2a multicenter, randomized, double-blind, placebo-controlled, parallel-arm domain within the act-global trial platform, to evaluate the dose-response,…NTS-521 | Neurotrauma Sciences, LLC | Ongoing |
| Jul 10, 2026 | Safety and efficacy of intravenous thrombolysis in patients with ischemic stroke on treatment with direct oral anticoagulants: do-it – the doac intravenous…Tnkase / Activase | Insel Gruppe AG, Inselspital (University Hospital) Bern | Pending |
| Jan 24, 2025 | Optimizing reperfusion to improve outcomes and neurologic function (ORION): a multicenter, double-blind, placebo controlled, randomized, parallel-group, phase…JX10 | Corxel Pharmaceuticals, Co, Ltd | Ongoing |
| Nov 1, 2024 | Phase 2/3 adaptive design, randomized double-blind placebo-controlled study to evaluate the safety and efficacy of DM199 for the treatment of acute ischemic…DM199 (rinvecalinase alfa) | DiaMedica Therapeutics | Ongoing |
| Oct 1, 2024 | A multicenter, double-blinded, placebo-controlled, single ascending dose, twopart, randomized, phase 2 clinical trial to assess safety, tolerability,…BB-031 | Basking Biosciences | Ongoing |
| Aug 15, 2024 | An investigator-initiated phase 3 multicentre open-label blinded-endpoint randomized controlled trial to evaluate the efficacy and safety of very low-dose…Edoxaban | Sunnybrook Research Institute | Pending |
| Dec 5, 2023 | A phase I, open-label, multicenter, pharmacokinetic, pharmacodynamic, and safety study of tenecteplase in adult patients with acute ischemic strokeTnkase | Roche | Pending |
| Dec 10, 2021 | A phase II, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of balovaptan in patients with acute ischemic…Balovaptan (RO5285119) | Roche | Closed |
| Sep 18, 2020 | A multicenter, randomized, double-blinded, placebo-controlled, parallel group, single-dose design to determine the efficacy and safety of nerinetide in…Nerinetide (NA-1) | Nono Inc | Closed |
| Dec 18, 2019 | A randomized, double-blind, placebo-controlled proof-of-concept study to assess the safety and efficacy of elezanumab in acute ischemic strokeElezanumab (ABT-555) | AbbVie | Closed |
| Oct 14, 2024 | GlyburideTreatment of large territory acute ischemic stroke | Remedy Pharmaceuticals, Inc. | Designated |
| Jan 12, 2017 | GlyburideTreatment of severe cerebral edema in patients with acute ischemic stroke | Remedy Pharmaceuticals, Inc. | Designated |
| Apr 11, 2014 | H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Se…Treatment of acute ischemic stroke patients presenting within 3 hours of symptom onset | NoNO, Inc. | Designated |
| Apr 18, 2011 | Tissue Plasminogen activatorTreatment of acute ischemic stroke (AIS) in children age 16 years and younger. | Catherine Amlie-Lefond, MD | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Oct 16, 2009 | Clopidogrel Viatris (previously Clopidogrel Taw Pharma)Clopidogrel · generic | Viatris Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA